Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic.
We consider the net benefits of pre-dispensing antivirals to high-risk individuals during an influenza pandemic, where the measure of the benefit is the number of severe outcomes (such as deaths or hospitalizations) prevented by antivirals in the whole population. One potential benefit of pre-dispensing is that individuals to whom antivirals have been pre-dispensed may be able to initiate treatment earlier than if they had to wait to obtain and fill a prescription, reducing their risk of progression to severe disease. If this benefit exceeds the side effects of misuse for the category of individuals to whom antivirals were pre-dispensed, and if antiviral supply exceeds overall population demand (which appears relevant for several countries including US in the 2009 H1N1 pandemic), pre-dispensing a quantity of antivirals not exceeding the difference between supply and demand is always beneficial. In this study, we consider the net benefits of pre-dispensing antivirals under various scenarios, including demand exceeding supply, and derive mathematical conditions under which antiviral pre-dispensing is advantageous on balance. For individuals whose relative risk of severe outcome is high enough, such as immunosuppressed individuals (particularly children) and possibly individuals with neurological disorders, pre-dispensing is always beneficial at a given level of antiviral stockpile with modest assumptions on the relative benefit of early treatment by a pre-dispensed course, regardless of the overall population demand for antivirals during the course of an epidemic. Making additional assumptions on either the overall population demand for antivirals (which appear relevant for the 2009 H1N1 pandemic) or on the relative benefit of pre-dispensing would make pre-dispensing net beneficial with inclusion of a larger number of persons such as pregnant women and morbidly obese adults.
Goldstein
Edward
E
Center for Communicable Disease Dynamics, Harvard School of Public Health, Boston, MA, USA. egoldste@hsph.harvard.edu
Miller
Joel C
JC
O'Hagan
Justin J
JJ
Lipsitch
Marc
M
D000998:Antiviral Agents / Q000008:administration & dosage*; D002959:Civil Defense / Q000379:methods*; D004196:Disease Outbreaks; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology*; D008962:Models, Theoretical
D000998:Antiviral Agents